FR2487200A1 - Composition pour la sterilisation de mammiferes males contenant des bacilles de calmette et guerin - Google Patents
Composition pour la sterilisation de mammiferes males contenant des bacilles de calmette et guerin Download PDFInfo
- Publication number
- FR2487200A1 FR2487200A1 FR7924868A FR7924868A FR2487200A1 FR 2487200 A1 FR2487200 A1 FR 2487200A1 FR 7924868 A FR7924868 A FR 7924868A FR 7924868 A FR7924868 A FR 7924868A FR 2487200 A1 FR2487200 A1 FR 2487200A1
- Authority
- FR
- France
- Prior art keywords
- calmette
- guerin
- composition
- bacilles
- bcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 9
- 241000124008 Mammalia Species 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- 241000304886 Bacilli Species 0.000 claims abstract description 3
- 241000894007 species Species 0.000 claims description 7
- 210000001550 testis Anatomy 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 239000002547 new drug Substances 0.000 claims 1
- 239000003206 sterilizing agent Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000021595 spermatogenesis Effects 0.000 description 5
- 239000003098 androgen Substances 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000002332 leydig cell Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000030663 Libido disease Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000322706A CA1189789A (en) | 1979-03-02 | 1979-03-02 | Sterilization process for mammals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2487200A1 true FR2487200A1 (fr) | 1982-01-29 |
| FR2487200B1 FR2487200B1 (OSRAM) | 1983-06-24 |
Family
ID=4113665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7924868A Granted FR2487200A1 (fr) | 1979-03-02 | 1979-10-05 | Composition pour la sterilisation de mammiferes males contenant des bacilles de calmette et guerin |
Country Status (5)
| Country | Link |
|---|---|
| CA (1) | CA1189789A (OSRAM) |
| DE (1) | DE2923333C2 (OSRAM) |
| FR (1) | FR2487200A1 (OSRAM) |
| GB (1) | GB2042889B (OSRAM) |
| IT (1) | IT1205229B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229234C2 (de) * | 1979-04-13 | 1986-06-19 | Philips Roxane, Inc., St. Joseph, Mo. | Chemische Kastration |
| US4720507A (en) * | 1984-03-05 | 1988-01-19 | University Of Western Ontario | Biological contraceptive and contraceptive technique for males |
| CA1239346A (en) * | 1985-06-04 | 1988-07-19 | Gursaran P. Talwar | Birth control vaccine |
-
1979
- 1979-03-02 CA CA000322706A patent/CA1189789A/en not_active Expired
- 1979-06-08 DE DE2923333A patent/DE2923333C2/de not_active Expired
- 1979-06-15 GB GB7920917A patent/GB2042889B/en not_active Expired
- 1979-10-05 FR FR7924868A patent/FR2487200A1/fr active Granted
-
1980
- 1980-01-30 IT IT19567/80A patent/IT1205229B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| DE2923333A1 (de) | 1980-09-11 |
| GB2042889A (en) | 1980-10-01 |
| IT8019567A0 (it) | 1980-01-30 |
| FR2487200B1 (OSRAM) | 1983-06-24 |
| CA1189789A (en) | 1985-07-02 |
| GB2042889B (en) | 1983-03-09 |
| DE2923333C2 (de) | 1986-07-24 |
| IT1205229B (it) | 1989-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auer et al. | The temporal evolution of hypoglycemic brain damage: II. Light-and electron-microscopic findings in the hippocampal gyrus and subiculum of the rat | |
| US5877169A (en) | Methods of treatment of ischemic damage | |
| FR2623401A1 (fr) | Compositions pour accroitre la penetration de substances a travers la peau, qui contiennent du monooleate de glycerol | |
| JPH10510532A (ja) | 製薬懸濁剤のための懸濁化剤としてのシクロデキストリン | |
| FR2853547A1 (fr) | Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production | |
| CA2382389C (fr) | Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale | |
| EP1592414A1 (fr) | Formulation liquide injectable de paracetamol | |
| FR2487200A1 (fr) | Composition pour la sterilisation de mammiferes males contenant des bacilles de calmette et guerin | |
| FR2817750A1 (fr) | Composition pharmaceutique de dronedarone pour administration parenterale | |
| US4720507A (en) | Biological contraceptive and contraceptive technique for males | |
| JPH07291806A (ja) | シクロデキストリン−殺生物剤複合体 | |
| MC1379A1 (fr) | Formule pharmaceutique isotonique stabilisee contenant un compose du mercure comme agent de conservation | |
| Logemann et al. | Antileukaemic activity of glycyrrhetinic acid | |
| FR2782608A1 (fr) | Complement alimentaire et procede pour la preparation d'un tel complement alimentaire | |
| David et al. | Failure of liver cirrhosis induction by thioacetamide in Nagase analbuminaemic rats | |
| EP0451299B1 (fr) | Support a commande magnetique a substance physiologiquement active et methode de realisation dudit support | |
| FR2914186A1 (fr) | Utilisation du phloroglucinol et/ou ses polymeres dans le traitement de processus inflammatoires | |
| JPH0311018A (ja) | 低アレルギー性ステロイド型麻酔／催眠薬組成物 | |
| Wang et al. | Nonexcretion of serum alkaline phosphatase by the liver and the pancreas of normal dogs | |
| Chi et al. | Ultrastructure of mast cell degranulation induced by eosinophil peroxidase: Use of diaminobenzidine cytochemistry by scanning electron microscopy. | |
| Lassiter et al. | Protective role of kynurenine 3-monooxygenase in allograft rejection and tubular injury in kidney transplantation | |
| Dera et al. | Protective effect of resveratrol against aluminium chloride (ALCL3) induced testicular damage in rats entails inhibition of intrinsic apoptotic pathway | |
| JPH04506795A (ja) | 抗ウイルス治療におけるｃ―２７ないしｃ―３２脂肪族アルコールの使用 | |
| FR2461463A1 (fr) | Procede de preparation d'eaux minerales ferrugineuses, eaux minerales obtenues par ce procede et leurs applications therapeutiques | |
| JP2010500871A (ja) | 成熟セルトリ細胞およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |